Formulation Scientist Interview Questions
& Model Answers, 2026

Characterise solubility across the physiological pH range, pKa and logP, solid-state form including polymorphs, hydrates and amorphous content, particle size and morphology, hygroscopicity, melting and thermal behaviour, and forced degradation to learn the degradation pathways. Then excipient compatibility. Choosing a dosage form before knowing the solid-state behaviour is how programmes discover a form change during stability.

Establish whether the limitation is solubility or dissolution rate, then choose an approach matched to the cause and the dose: particle size reduction, salt or cocrystal formation where ionisable, amorphous solid dispersions with a polymer to inhibit recrystallisation, lipid-based systems, or a formulation with solubilising excipients. Each brings its own stability and manufacturability burden, and the trade-off should be stated rather than glossed over.

By function first — filler, binder, disintegrant, lubricant, stabiliser — then compendial grade and supplier consistency, compatibility demonstrated through binary studies with the drug substance, precedent of use at the intended level and route, and impact on the critical quality attributes. Lubricant level and blending time in particular affect dissolution and tablet strength, which is a common and avoidable late-stage surprise.

Long-term, intermediate and accelerated conditions per ICH guidance for the intended climatic zones, in the proposed container closure system, with timepoints appropriate to the phase, testing appearance, assay, degradation products, dissolution and any dosage-form-specific attributes, plus photostability and in-use studies where relevant. Enough batches to support the claim. The specification and stability-indicating methods must be in place before the study starts.

A stability-indicating assay and impurity method capable of separating the degradants found in forced degradation, a discriminating dissolution method that reflects meaningful formulation differences rather than passing everything, content uniformity, and solid-state methods such as X-ray diffraction and thermal analysis to track form. A dissolution method that cannot distinguish a good batch from a bad one is worse than useless.

Define the quality target product profile, identify critical quality attributes, link them to material attributes and process parameters through risk assessment, then use designed experiments to establish which parameters actually matter and over what range, producing a design space and a control strategy. Executed properly it reduces late failures; used as vocabulary over one-factor-at-a-time work it convinces nobody on a technical panel.

Panels want the investigation — degradation pathway, excipient interaction, moisture, packaging — and the reformulation or packaging change that resolved it, plus what changed in the earlier screening.

Strong answers identify the scale-dependent variable — shear, drying, blend time, compression speed — rather than treating it as inexplicable, and describe the process understanding that resolved it.

Interviewers look for early engagement so stability-indicating and dissolution methods are ready when the formulation needs them, and for an understanding of method capability and variability rather than treating an analytical result as absolute truth.

Good answers show data-driven recommendation to change direction and clear communication of the reasoning, which is far more valuable than persisting with a formulation that cannot be manufactured.

Anchor and position. The BLS OEWS May 2025 national median for chemists is $91,240 a year ($43.87/hr), with the top 10% above $160,830. Then place yourself on dosage forms and modalities you have developed, phase experience through to commercial, and whether you have taken products through technology transfer and regulatory filings.

It typically affects entry level and the speed of progression into independent project leadership more than it changes the ceiling. Demonstrated development experience across dosage forms and successful transfers weighs heavily in interviews regardless of degree, so position on what you have delivered rather than on credentials alone.

Laboratory equipment and pilot-plant access, the modalities and dosage forms you will work on, publication and patent policy, conference attendance, and whether you own projects or support them. Access to pilot-scale equipment is what makes a formulation scientist's experience transferable.